The National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) and Response Biomedical Corporation signed a funding agreement last week worth more than $400,000 to develop a new rapid test for sepsis.
Response Biomedical Corporation will use the funding – up to $412,000 – to develop a new biomarker test for sepsis that may help the company to expand sales to current RAMP test platform customers and to expand sales into new markets.
The company's RAMP Platform consists of a reader and single-use disposable test cartridges.
“We are extremely pleased to have received financial support and technological advisory services from NRC-IRAP,” Barbara Kinnaird, the chief operating officer at Response, said. “This support will allow us to expand our RAMP test menu with a new primary diagnostic tool that can be used to quickly guide appropriate therapy for patients arriving at hospital emergency departments worldwide.”
Response Biomedical Corporation creates and sells rapid onsite diagnostic tests for use with its own platform for use in a variety of locales – including clinical use, biodefense and environmental settings. Currently, the company offers RAMP tests for congestive heart failure and a variety of other medical conditions as well as an environmental test for West Nile. In the biodefense sector, the company offers onsite testing for anthrax.